Hepatitis C: Commercial Laboratory Residual Sera, November 2023–September 2024

This dataset provides hepatitis C virus antibody and RNA test results from all 50 states and the District of Columbia using a convenience sample of de-duplicated, deidentified residual serum specimens from a large commercial laboratory. Specimens were collected for any routine clinical screening or diagnostic testing purposes and were tested for hepatitis C virus during November 2023 through September 2024 proportional to the percent of the U.S. population in each jurisdiction and stratified by two age groups (18–≤49 years and 50–≤75 years) within sex. Specimens with reactive or equivocal hepatitis C virus antibody results were reflexed to HCV RNA testing. These data underly the manuscript published in Clinical Infectious Diseases, “Estimated hepatitis C prevalence and viral clearance using residual sera from a large commercial laboratory — November 2023–September 2024” (doi 10.1093/cid/ciag007).

Data Limitations:

1. Generalizability. Persons who had blood drawn for routine screening or clinical care by a single commercial laboratory might not be representative of the general U.S. adult population.
2. Convenience sampling is subject to potential biases.
3. Specimens from carceral facilities or incarcerated persons are not representative of the overall carceral population in the United States; carceral specimens are overrepresented from some jurisdictions and underrepresented from others.